3-amino-4-(isopentylamino)benzonitrile | 475489-78-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-amino-4-(isopentylamino)benzonitrile
• 英文别名: 3-amino-4-(3-methylbutylamino)benzonitrile
• CAS: 475489-78-2
• 化学式: C₁₂H₁₇N₃
• 分子量: 203.287
• InChiKey: RYIRLUVIZDWFIR-UHFFFAOYSA-N

物化性质

• 沸点：
  378.6±32.0 °C(Predicted)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-amino-4-(isopentylamino)benzonitrile 在 sodium hydroxide 、 lithium aluminium tetrahydride 、 氯化亚砜 、 TEA 、 硫酸 、 三溴化硼 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 生成 methanesulfonic acid 2-(3-isopropyl-2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-1-(3-methyl-butyl)-1H-benzoimidazol-5-ylmethyl ester
  参考文献：
  名称：

  Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity

  摘要：

  Extensive SAR studies and optimization of ADME properties of benzimidazol-2-one derivatives led to the identification of BMS-433771 (3) as an orally active RSV fusion inhibitor. In order to extend the structure-activity relationships for this compound series, substitution of the benzimidazole ring was examined with a view to establishing additional productive interactions between the inhibitor and functionality present in the proposed binding pocket. Amongst the compounds synthesized, the 5-aminomethyl analogue 10aa demonstrated potent antiviral activity towards wild-type RSV and retained excellent inhibitory activity towards a virus that had been developed to express resistance to BMS-433771 (3), data consistent with an additional productive interaction between the inhibitor and the fusion protein target. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.102
• 作为产物：
  描述：

  4-(isopentylamino)-3-nitrobenzonitrile 在 盐酸 、 tin(ll) chloride 作用下， 以 水 为溶剂， 反应 1.5h， 以91%的产率得到3-amino-4-(isopentylamino)benzonitrile
  参考文献：
  名称：

  了解新的苄腈对酸性介质中低碳钢的腐蚀抑制作用：从实验和计算研究中得出的见解

  摘要：

  合成了两种苄腈衍生物，即4-（异戊基氨基）-3-硝基苄腈（PANB）和3-氨基-4-（异戊基氨基）苄腈（APAB），并在1 M HCl溶液中作为低碳钢（MS）的缓蚀剂进行了评估通过重量分析，电位动力学极化（PDP）曲线，电化学阻抗谱（EIS）方法以及密度泛函理论（DFT）和分子动力学（MD）模拟得出303K。结果表明，所测试的化合物是低碳钢的优异腐蚀抑制剂，PANB具有优异的性能。极化测量表明，PANB和APAB表现为混合型抑制剂。根据EIS研究，极化电阻取决于抑制剂的浓度。低碳钢表面上PANB和APAB的吸附服从Langmuir' 吸附等温线。一方面，DFT和MD模拟用于解释分子结构对缓蚀效率的影响，另一方面模拟苄腈衍生物在低碳钢表面的吸附。通过使用扫描电子显微镜（SEM）和原子力显微镜（AFM）证实了碳钢在1 M HCl中的保护作用。电化学，DFT和MD模拟结果吻合良好。通过使用扫描电

  DOI：

  10.1016/j.molliq.2018.06.103

文献信息

• Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion
  作者：G. Stuart Cockerill、Richard M. Angell、Alexandre Bedernjak、Irina Chuckowree、Ian Fraser、Jose Gascon-Simorte、Morgan S. A. Gilman、James A. D. Good、Rachel Harland、Sara M. Johnson、John H Ludes-Meyers、Edward Littler、James Lumley、Graham Lunn、Neil Mathews、Jason S. McLellan、Michael Paradowski、Mark E. Peeples、Claire Scott、Dereck Tait、Geraldine Taylor、Michelle Thom、Elaine Thomas、Carol Villalonga Barber、Simon E. Ward、Daniel Watterson、Gareth Williams、Paul Young、Kenneth Powell

  DOI：10.1021/acs.jmedchem.0c01882

  日期：2021.4.8

  RV521 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property directed hit profiling exercise at Reviral. This exercise encompassed collaborations with a number of contract organizations with collaborative medicinal chemistry and virology during the optimization phase

  RV521是口服呼吸道合胞病毒（RSV）融合的生物可利用抑制剂，在基于铅的最佳化工艺优化后进行鉴定，该铅是基于Reviral的物理特性指导命中分析运动而产生的命中。除了在临床前和临床评估中作为化合物使用的化合物外，该练习还包括在优化阶段与许多合同组织在药物化学和病毒学方面的合作。RV521的平均IC 50在RSV感染的Balb / C小鼠模型中，针对一组具有抗病毒效力的RSV A和B实验室菌株和临床分离株检测1.2 nM的抗性。临床前物种的口服生物利用度范围从42％到> 100％，具有高效渗透到肺组织的证据。在健康成人志愿者中，实验性感染RSV的病毒与安慰剂相比，具有很强的抗病毒作用，其病毒载量和症状明显减少。
• [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIVARAL AGENTS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE ET LEUR UTILISATION COMME AGENTS ANTIVIRAUX
  申请人：ASTRAZENECA UK LTD

  公开号：WO2010103306A1

  公开（公告）日：2010-09-16

  The invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined in the specification, and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of respiratory syncytial virus (RSV).

  该发明提供了以下化合物的公式(I)：其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11和R12如规范中所定义，并且其光学异构体、拉丁酸盐和互变异构体，以及其药学上可接受的盐；以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的使用。这些化合物在呼吸道合胞病毒（RSV）的治疗中很有用。
• NOVEL COMPOUNDS 660
  申请人：Blade Helen

  公开号：US20100278835A1

  公开（公告）日：2010-11-04

  The invention provides compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are as defined in the specification, and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of respiratory syncytial virus (RSV).

  本发明提供了式(I)的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11和R12如规范中所定义，以及其光学异构体、消旋体和互变异构体，以及其药学上可接受的盐；以及它们的制备方法，含有它们的制药组合物以及它们在治疗中的应用。这些化合物在呼吸道合胞病毒(RSV)的治疗中是有用的。
• Synthesis of some new 2-substituted-phenyl-1H-benzimidazole-5-carbonitriles and their potent activity against candida species
  作者：Hakan Göker、Canan Kuş、David W. Boykin、Sulhiye Yildiz、Nurten Altanlar

  DOI：10.1016/s0968-0896(02)00103-7

  日期：2002.8

  New 2-substituted-phenyl-1H-benzimidazole-5-carboxylic acids (35, 38), ethyl-5-carboxylate (36), -5-carboxamides (37, 39),-5-carboxaldeliyde (42), -5-chloro (40), -5-trifluoromethyl (41), and -5-carbonitriles (44-53, 55-67), -6-carbonitrilc (54) were prepared and evaluated in vitro against Candida species. The cyano substituted compounds 53, 57, 58 and 61 exhibited the greatest activity with MIC values of 3.12 mug/mL, values similar to that of fluconazole. (C) 2002 Elsevier Science Ltd. All rights reserved.
• Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity
  作者：Xiangdong Alan Wang、Christopher W. Cianci、Kuo-Long Yu、Keith D. Combrink、Jan W. Thuring、Yi Zhang、Rita L. Civiello、Kathleen F. Kadow、Julia Roach、Zhufang Li、David R. Langley、Mark Krystal、Nicholas A. Meanwell

  DOI：10.1016/j.bmcl.2007.05.102

  日期：2007.8

  Extensive SAR studies and optimization of ADME properties of benzimidazol-2-one derivatives led to the identification of BMS-433771 (3) as an orally active RSV fusion inhibitor. In order to extend the structure-activity relationships for this compound series, substitution of the benzimidazole ring was examined with a view to establishing additional productive interactions between the inhibitor and functionality present in the proposed binding pocket. Amongst the compounds synthesized, the 5-aminomethyl analogue 10aa demonstrated potent antiviral activity towards wild-type RSV and retained excellent inhibitory activity towards a virus that had been developed to express resistance to BMS-433771 (3), data consistent with an additional productive interaction between the inhibitor and the fusion protein target. (c) 2007 Elsevier Ltd. All rights reserved.